Cover Image
Market Research Report

Essential Thrombocythemia - Pipeline Review, H1 2020

Published by Global Markets Direct Product code 229782
Published Content info 115 Pages
Delivery time: 1-2 business days
Price
Back to Top
Essential Thrombocythemia - Pipeline Review, H1 2020
Published: April 30, 2020 Content info: 115 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Essential Thrombocythemia - Pipeline Review, H1 2020, provides an overview of the Essential Thrombocythemia (Oncology) pipeline landscape.

Essential thrombocythemia is a chronic myeloproliferative neoplasm in which cells in the bone marrow that produce the blood cells develop and function abnormally. In essential thrombocythemia, there is mainly an overproduction of platelet forming cells (megakaryocytes) in the marrow. Symptoms of essential thrombocythemia include headache, dizziness, weakness or numbness on one side of the body, slurred speech and transient ischemic attacks.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Essential Thrombocythemia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Essential Thrombocythemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Essential Thrombocythemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Essential Thrombocythemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 2, 6 and 6 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Essential Thrombocythemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Essential Thrombocythemia (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Essential Thrombocythemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Essential Thrombocythemia (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Essential Thrombocythemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Essential Thrombocythemia (Oncology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Essential Thrombocythemia (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Essential Thrombocythemia (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC12158IDB

Table of Contents

  • Introduction
  • Essential Thrombocythemia - Overview
  • Essential Thrombocythemia - Therapeutics Development
  • Essential Thrombocythemia - Therapeutics Assessment
  • Essential Thrombocythemia - Companies Involved in Therapeutics Development
  • Essential Thrombocythemia - Drug Profiles
  • Essential Thrombocythemia - Dormant Projects
  • Essential Thrombocythemia - Discontinued Products
  • Essential Thrombocythemia - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Essential Thrombocythemia, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Essential Thrombocythemia - Pipeline by AbbVie Inc, H1 2020
  • Essential Thrombocythemia - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
  • Essential Thrombocythemia - Pipeline by Imago BioSciences Inc, H1 2020
  • Essential Thrombocythemia - Pipeline by Incyte Corp, H1 2020
  • Essential Thrombocythemia - Pipeline by IO Biotech ApS, H1 2020
  • Essential Thrombocythemia - Pipeline by Italfarmaco SpA, H1 2020
  • Essential Thrombocythemia - Pipeline by MEI Pharma Inc, H1 2020
  • Essential Thrombocythemia - Pipeline by Millennium Pharmaceuticals Inc, H1 2020
  • Essential Thrombocythemia - Pipeline by PharmaEssentia Corp, H1 2020
  • Essential Thrombocythemia - Pipeline by Sino Biopharmaceutical Ltd, H1 2020
  • Essential Thrombocythemia - Dormant Projects, H1 2020
  • Essential Thrombocythemia - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Essential Thrombocythemia, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Back to Top